SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals rises as its arm launches Sugammadex Injection

29 Jul 2026 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 2212.05, up by 27.15 points or 1.24% from its previous closing of Rs. 2184.90 on the BSE.

The scrip opened at Rs. 2209.05 and has touched a high and low of Rs. 2,216.00 and Rs. 2,188.70 respectively. So far 165 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.

Last one week high and low of the scrip stood at Rs. 2242.25 and Rs. 2,179.40 respectively. The current market cap of the company is Rs. 61658.05 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC.

According to IQVIA sales data for the 12-month period ending May 2026, the BRIDION Injection, 100 mg/mL market achieved annual sales of around $1.6 billion.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma. Share Price

2201.20 16.30 (0.75%)
29-Jul-2026 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1974.80
Dr. Reddys Labs. 1143.90
Cipla 1481.00
Lupin 2442.65
Zydus Lifesciences 1118.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: